Pesquisar
Telix Pharmaceuticals Ltd
TLXAdicionar à lista de desejos
10.560USD
-0.300-2.76%
Fechamento 05/15, 16:00（ET）Cotações atrasadas em 15 min
0.00Valor de mercado
--P/L TTM
Mais detalhes de Telix Pharmaceuticals Ltd Empresa
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Informações de Telix Pharmaceuticals Ltd
Código da empresaTLX
Nome da EmpresaTelix Pharmaceuticals Ltd
Data de listagemNov 15, 2017
CEOOrtiz (Raphaeel)
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscal- -
Endereço55 Flemington Road
CidadeMELBOURNE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal3051
Telefone61390933855
Sitehttps://telixpharma.com/
Código da empresaTLX
Data de listagemNov 15, 2017
CEOOrtiz (Raphaeel)
Executivos da empresa Telix Pharmaceuticals Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Mr. Kevin Richardson
Mr. Kevin Richardson
Chief Executive Officer - Telix Precision Medicine
Chief Executive Officer - Telix Precision Medicine
--
--
Mr. Raphaeel Ortiz
Mr. Raphaeel Ortiz
Chief Executive Officer - Telix International
Chief Executive Officer - Telix International
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qui, 14 de mai
Atualizado em: qui, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Portland Investment Counsel Inc.
0.08%
Lazard Asset Management, L.L.C.
0.07%
Raiffeisen Bank International AG
0.04%
Fidelity Management & Research Company LLC
0.04%
Private Advisor Group LLC
0.01%
Outro
99.76%
Investidores
Investidores
Proporção
Portland Investment Counsel Inc.
0.08%
Lazard Asset Management, L.L.C.
0.07%
Raiffeisen Bank International AG
0.04%
Fidelity Management & Research Company LLC
0.04%
Private Advisor Group LLC
0.01%
Outro
99.76%
Tipos de investidores
Investidores
Proporção
Investment Advisor
0.24%
Investment Advisor/Hedge Fund
0.09%
Research Firm
0.06%
Hedge Fund
0.03%
Bank and Trust
0.02%
Outro
99.57%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
61
1.47M
0.43%
+326.20K
2025Q4
40
845.28K
0.25%
+354.64K
2025Q3
25
456.14K
0.13%
+379.51K
2025Q2
11
269.45K
0.08%
+265.72K
2025Q1
6
20.71K
0.01%
+16.98K
2024Q4
1
3.73K
0.00%
+3.73K
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Portland Investment Counsel Inc.
266.20K
0.08%
+138.20K
+107.97%
Dec 31, 2025
Lazard Asset Management, L.L.C.
250.52K
0.07%
+135.89K
+118.56%
Dec 31, 2025
Fidelity Management & Research Company LLC
123.57K
0.04%
+5.09K
+4.30%
Dec 31, 2025
Private Advisor Group LLC
46.34K
0.01%
+4.23K
+10.05%
Dec 31, 2025
Marshall Wace LLP
46.66K
0.01%
-1.92K
-3.94%
Dec 31, 2025
JPMorgan Private Bank (United States)
44.49K
0.01%
+19.14K
+75.47%
Dec 31, 2025
Quadrature Capital LLP
36.83K
0.01%
+36.83K
--
Dec 31, 2025
Mariner Wealth Advisors
36.58K
0.01%
+36.58K
--
Dec 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
